Dallas, TX 2025 Southwest IDEAS Conference November 20, 2025 Forward-looking statements and Non-GAAP information This presentation contains forward-looking statements with predictions, projections and other statements about future events. These statements are made on the basis of management's views and assumptions regarding future events and business performance. We use words such as "believe," "expect," "anticipate," "intends," "estimate," "forecast," "project," "will," "plan," "should" and similar express ...

Important Notice Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical in nature and can be identified by words such as "anticipate," "estimate," "will," "should," "may," "expect," "project," "believe," "intend," "seek," "plan" and similar expressions or their negative forms, or by references to strategy, plans, or intentions. F ...

New Jersey Resources (NYSE:NJR) Q4 2025 Earnings Call November 20, 2025 10:00 AM ET Speaker2 Ladies and gentlemen, thank you for standing by. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to the New Jersey Resources Fiscal 2025 Fourth Quarter and Year-End Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like ...

Repay (NasdaqCM:RPAY) FY Conference November 20, 2025 10:00 AM ET Speaker2All right. Why don't we get started? It's about 9:00. Good morning, everyone, and thank you for joining us today. My name is Chuck Napehan. This is my partner on the payments and fintechs team, Alex Newman. Joining us today from Repay is CEO John Morris, newly appointed CFO Rob Hauser, and over there is Stewart Grisante, head of investor relations. Gentlemen, I really appreciate you guys being here and making the trip, and pleased to ...

Lifecore Biomedical (NasdaqGS:LFCR) FY Conference November 20, 2025 10:00 AM ET Speaker2All right. It's the top of the hour, so we'll go ahead and get started. Welcome to day three of the 2025 Stevens Investment Conference. I'm Mac Etosh, the life science tools and pharma services analyst over here at Stevens. I'm pleased to be joined today by Lifecore Biomedical's CEO, Paul Josephs, and CFO, Ryan Lake. Paul, Ryan, I'll turn it over to you for any opening comments while we jump into Q&A.Speaker1Mac, thank y ...

Construction Partners (NasdaqGS:ROAD) Q4 2025 Earnings Call November 20, 2025 10:00 AM ET Speaker7 Greetings. Welcome to Construction Partners' fourth-quarter earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

NASDAQ: PAYS 17th Annual Southwest IDEAS Investor Conference 11.20.2025 Important Notices Forward-Looking Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ("Forward-Looking Statements"). All statements other than statements of historical fact included in this presentation are Forward-Looking Statements. These Forward-Looking Statements are based o ...

Summary of Vitesse Energy Conference Call Company Overview - **Company Name**: Vitesse Energy - **Ticker**: VTS - **Business Model**: Primarily a non-operated oil and gas company participating in wells in North Dakota's Bakken Play and Colorado's DJ Basin [2][3] Key Industry Insights - **Market Position**: Vitesse holds over 50,000 net acres in North Dakota and engages in acquisitions to manage capital spending [3][4] - **Production Metrics**: Current production is approximately 17,000 BOE per day, with 65% of production from oil, contributing to 90% of revenue [10][21] - **Technological Advancements**: The industry is seeing longer laterals (up to four miles) which improve production efficiency and economics [5][12][19] Financial Strategy - **Dividend Policy**: Vitesse prioritizes maintaining a dividend of over 10%, viewing it as crucial for capital allocation [4][6] - **Capital Allocation**: The company plans to reduce capital spending in response to market conditions, focusing on maintaining cash flows and dividend payments [7][24] - **Hedging Strategy**: Approximately 45% of oil and gas production is hedged, with a floor around $64 and a ceiling around $66, to mitigate price volatility [20] Recent Developments - **Acquisition of Lucero Oil and Gas**: This acquisition allows Vitesse to operate some wells, marking a shift from being solely non-operated [21][22] - **Legal Settlement**: Vitesse settled a lawsuit with Hess regarding royalty payments, resulting in improved contract terms [27] Market Outlook - **Oil Price Predictions**: The company anticipates oil prices to remain in the high $50s to low $60s, with potential for a slowdown in operations if prices drop below $50 [23][24] - **Future Opportunities**: Vitesse aims to leverage its strong balance sheet to capitalize on acquisition opportunities as the market adjusts [24][25] Additional Insights - **Data Utilization**: Vitesse employs a vast data system to analyze operator performance and optimize capital investment decisions [11][14] - **AI Integration**: The company is integrating AI to enhance data accessibility and operational efficiency across departments [14] Conclusion Vitesse Energy is strategically positioned in the Bakken Play with a focus on maintaining dividends and managing capital efficiently amidst fluctuating oil prices. The recent acquisition and technological advancements in drilling are expected to enhance production capabilities and financial stability moving forward.

Summary of Research Solutions (NasdaqCM:RSSS) FY Conference Call Company Overview - **Company**: Research Solutions, Inc. (RSSS) - **Industry**: Scientific research and document delivery - **Business Model**: Transitioning from a transactional model to a SaaS platform model focused on research and development (R&D) [2][9][20] Key Points and Arguments Business Transformation - The company is undergoing a significant transformation from providing peer-reviewed scientific research articles to offering a sophisticated SaaS product called Article Galaxy, which streamlines the research process for corporate clients [2][3][4] - Article Galaxy allows researchers to access scientific papers through a single search, enhancing efficiency and reducing costs [3][4] Product Offerings - **Article Galaxy**: A platform for accessing scientific research papers, now includes rental capabilities and rights management features [4][5] - **Scite**: An AI-powered discovery product acquired by the company, which enhances the research process by providing insights beyond paywalls [8][20] - **DocDel (Document Delivery)**: The transactional business segment, which is currently facing challenges due to customer churn [6][9][15] Financial Performance - The company reported a 20% organic growth in Annual Recurring Revenue (ARR), which is now over $21 million [16][19] - The platform business has a gross margin of approximately 85%, while the transactional business has a gross margin of 24-25% [13][16] - The overall corporate blended gross margin has improved from 40% to over 50% in the past two years [17] Market Opportunity - The Total Addressable Market (TAM) for the B2B segment is estimated at $4 billion, with significant growth potential in the B2C segment as well [12][21] - The company serves a diverse range of verticals, including pharmaceuticals, biotech, and academic institutions, with about half of its revenue coming from the healthcare sector [11][12][21] Customer Dynamics - The company has approximately 1,500 customers, with a typical customer lifetime value of 6-8 years [11][21][42] - Renewal rates are around 90%, with top-tier customers achieving renewal rates of 97-98% [41][42] - Challenges in the transactional business are attributed to customer churn and the increasing availability of open-access content [33][36] Strategic Focus - The company aims to be the "Bloomberg terminal" for research, providing comprehensive solutions across the research workflow [20] - There is an ongoing discussion about share buybacks as a strategy to enhance shareholder value, especially given the current trading multiples [23][24] AI Integration - AI is viewed as both a threat and an opportunity; the company is focused on integrating AI into its workflow to enhance its offerings while ensuring compliance with copyright regulations [27][28][29] Future Outlook - The company expects continued growth in its platform business, while the transactional business may remain flat due to market dynamics [10][15] - The management is optimistic about the long-term growth potential and is focused on executing its strategic plan [19][21] Additional Important Insights - The company has made two acquisitions in the past five years to enhance its discovery capabilities [7][20] - The management is implementing a new software tool to proactively manage customer relationships and reduce churn [43] - The competitive landscape is evolving, with many new entrants in the research AI space, but the company believes it has a unique position due to its access to comprehensive content [29][30]

Summary of Merck & Co (NYSE:MRK) 2025 Conference Call Company Overview - **Company**: Merck & Co (also known as MSD in certain regions) [2][4] - **Focus**: The company is actively involved in the development of innovative therapies, particularly in the fields of infectious diseases, oncology, and chronic conditions. Key Industry Insights Acquisition and Product Development - **Cidara Acquisition**: Merck's acquisition of Cidara is aimed at enhancing its vaccine-adjacent business, particularly in the flu market with a long-acting antiviral [3][5] - **Long-Acting Antiviral**: The new antiviral shows 76% efficacy against influenza, with a potential market of 110 million people in the U.S., including 85 million with underlying health conditions [7][8] - **Economic Impact**: The previous flu season saw 1.6 million hospitalizations in the U.S., highlighting the economic and health benefits of the new antiviral [8][9] Regulatory and Market Strategy - **FDA Engagement**: The FDA has shown interest in expanding the patient population for the phase three program of the antiviral, indicating alignment with public health strategies [11][13] - **Market Adoption**: The company is optimistic about the uptake of the antiviral, emphasizing its strain-agnostic nature and potential for broad public health impact [15][16] Oncology Developments - **Winrevair for PAH**: The launch of Winrevair has been transformative for patients with pulmonary arterial hypertension (PAH), with ongoing patient initiation rates of about 500 per month in the U.S. [21][23] - **Sactuzumab Govitecan**: This drug is positioned as a versatile treatment for various cancers, with 15 registration studies ongoing, aiming to provide effective options for community oncologists [48][49] HIV Treatment Innovations - **Islatravir/Derivery**: A new daily two-drug regimen that is non-inferior to Biktarvy, with a PDUFA date set for April next year. This regimen aims to address the need for alternatives to integrase inhibitors [58][66] - **Monthly PrEP Option**: A long-acting oral PrEP option is in development, which could appeal to patients preferring convenience over injections, representing a multi-billion dollar opportunity in the HIV market [63][65] Additional Insights - **Market Needs**: There is a significant unmet medical need in various patient populations, particularly in oncology and chronic diseases, which Merck aims to address through innovative therapies [27][29] - **Patient-Centric Approach**: The company emphasizes the importance of patient education and government support in driving product uptake, especially in the context of vaccine hesitancy [10][11] Conclusion Merck & Co is strategically positioning itself in the pharmaceutical market through acquisitions, innovative product development, and a focus on addressing unmet medical needs across various therapeutic areas. The company's proactive engagement with regulatory bodies and emphasis on patient-centric solutions are expected to drive future growth and market adoption.